Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the appointment of Kim Stratton as the new Chief Executive Officer of Orphazyme, succeeding Anders Hinsby. Kim will take up her new position on October 1 2019.
As Orphazyme enters a new chapter in its development, from being an entrepreneurial R&D company to a company with significant growth aspirations, an emerging late-stage pipeline and moving into the pre-commercial phase, Anders Hinsby initiated discussions with the Board of Directors to resign from his position as Chief Executive Officer.
Anders co-founded Orphazyme ten years ago and has led its successful evolution. Anders Hinsby will remain with the company through the transition period.
Georges Gemayel, Chairman of Orphazyme said: “I am very pleased to welcome Kim Stratton as the new Chief Executive Officer of Orphazyme. Kim is a proven leader with valuable experience in orphan drug development, a deep understanding of the dynamics of the global commercial landscape and a solid track record in delivering sustainable business results.
“With these strengths, Kim is well-placed to lead Orphazyme’s transition into a commercial biopharmaceutical company. I look forward, along with the rest of the Board, to supporting Kim in continuing to successfully develop Orphazyme.”